ArticleAlzheimer's research & therapy2020
Normalization of CSF pTau measurement by Aβ
Article in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Diagnostic value of blood p-tau subtypes in Alzheimer's disease progression and pathology: systematic review and meta-analysis.European archives of psychiatry and clinical neuroscience · 2026Pooled it
- MCH-Guard: Multimodal machine learning framework for risk stratification of cerebral microhemorrhage risk in the Alzheimer's Disease Neuroimaging Initiative.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Classification of tau status with machine learning models in amyloid-positive cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP.Acta neuropathologica · 2026Article
- Reference proteins to improve Core 1 and Core 2 Alzheimer's disease CSF and plasma biomarkers.Brain : a journal of neurology · 2026Article
- Correlations of CSF Biomarkers of Alzheimer's Disease with Cognitive Measures in MCI and AD Dementia: A Cross-Sectional Analysis.Research square · 2025Article
- Detecting Alzheimer's disease using digital virtual reality cognitive tests.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Higher plasma soluble TREM2 correlates with reduced cerebral tau accumulation in Alzheimer's disease.Molecular psychiatry · 2025Article
- Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease.JAMA neurology · 2025Article
- Presynaptic loss and axonal degeneration synergistically correlate with longitudinal neurodegeneration and cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer's disease.Molecular neurodegeneration · 2025Article
- Applying machine learning to high-dimensional proteomics datasets for the identification of Alzheimer's disease biomarkers.Fluids and barriers of the CNS · 2025Article
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Plasma N-terminal tau fragment is an amyloid-dependent biomarker in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Association of plasma biomarkers of Alzheimer's pathology and neurodegeneration with gait performance in older adults.Communications medicine · 2025Article
- Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseases.Scientific reports · 2025Article
- Article
- Establishing tau-PET cut-points for cognitive diagnosis withImaging neuroscience (Cambridge, Mass.) · 2025Article
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Biological mechanisms of resilience to tau pathology in Alzheimer's disease.Alzheimer's research & therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAlzheimer's disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between these measurements and their relative ability to predict subsequent disease progression.
methodsIn 219 cognitively unimpaired and 122 impaired Alzheimer's Disease Neuroimaging Initiative participants with concurrent amyloid-β (Aβ) PET (
resultsThe use of a CSF pTau/Aβ
conclusionsTogether, these findings suggest that CSF pTau/Aβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.